January 8, 2021 PR/Corporate

Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. “I am delighted to have Mark... Read more

January 8, 2021 PR/Corporate

Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. “I am delighted to have Mark... Read more

January 8, 2021 PR/Corporate

Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. Read more

January 8, 2021 Atomic Spectroscopy Chromatography Life Science Tools PR/Corporate

Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for... Read more

January 8, 2021 Atomic Spectroscopy Chromatography Life Science Tools PR/Corporate

Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for... Read more

January 8, 2021 Atomic Spectroscopy Chromatography Life Science Tools PR/Corporate

Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for... Read more

January 7, 2021 Environ, Ag./Food & Bev Lab Top-10 Life Science Tools PR/Corporate

Danaher Schedules Fourth Quarter 2020 Earnings Conference Call

WASHINGTON, Jan. 7, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2020 on Thursday, January 28, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s... Read more

January 7, 2021 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics

Adds to MilliporeSigma’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing MilliporeSigma portfolio Burlington, Massachusetts, January 7, 2020 — MilliporeSigma today... Read more